The approval of two chimeric antigen receptor-modified T cell types by the US Food and Drug Administration (FDA) for the treatment of hematologic malignancies is a milestone in immunotherapy; however, the application of CAR-T cells has been limited by antigen escape and on-target, off-tumor toxicities. Therefore, it may be a potentially effective strategy to select appropriate targets and to combine multi-antigen-targeted CAR-T cells with "OR", "AND" and "NOT" Boolean logic gates. We summarize the current limitations of CAR-T cells as well as the efficacy and safety of logic-gated CAR-T cells in antitumor therapy. This review will help to explore more optimized strategies to expand the CAR-T cell therapeutic window.
CITATION STYLE
Han, X., Wang, Y., Wei, J., & Han, W. (2019, November 29). Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy. Journal of Hematology and Oncology. BioMed Central Ltd. https://doi.org/10.1186/s13045-019-0813-7
Mendeley helps you to discover research relevant for your work.